CNC

Business profile & competitive position

Centene Corp. (CNC) operates in the Healthcare sector, specifically the Medical - Healthcare Plans industry. The company describes itself as the nation’s largest managed care organization focused on underserved populations. It delivers care through Medicaid, Medicare Advantage, Prescription Drug Plans (PDP), Medicare Supplement products, and commercial plans sold on the Health Insurance Marketplace. Service is delivered through local brands and teams that are backed by national infrastructure, and the company also connects members to non-medical supports such as food, housing, utilities, and transportation.

The 10-K excerpt indicates that, for 2025, $194.8 billion in total revenue was split 57% Medicaid, 21% Commercial, 19% Medicare, and 3% Other. Membership reached 27.6 million as of December 31, 2025, including 12.5 million Medicaid members, 5.5 million Marketplace members, and 8.1 million stand-alone PDP members. Centene also identifies itself as the largest Medicaid insurer, the largest Marketplace insurer, and the largest stand-alone PDP provider in the United States.

Scale is the clearest competitive feature the data supports: a 27.6 million-member base and national Medicaid/Marketplace/PDP leadership positions create purchasing power, provider-network leverage, and administrative cost density. That said, competitive advantage must also be read against profitability. The company’s trailing net margin is negative 2.6% and return on equity is negative 24.0%. A negative ROE of that size means the business is currently destroying equity earnings, not compounding them. In a managed-care context, that profile typically reflects compressed premium spreads, utilization volatility, or pricing actions taken to retain membership. The moat here is volume and market position rather than pricing power or fat margins.

Financial posture

As of the current snapshot, CNC’s market capitalization is $31.3 billion, the stock trades at $63.45, and the trailing P/E ratio is negative 6.1. A negative P/E is not a valuation discount in the traditional sense; it reflects that trailing earnings are negative. That impression is confirmed by the negative 2.6% net margin and negative 24.0% ROE. The market is therefore not pricing a stream of current profits, but rather a future normalization story.

The company’s beta is 1.11, meaning the stock has historically moved slightly more than the overall market. Technical context from the snapshot shows an RSI of 48.2 and a 50-day EMA of $64.05, essentially leaving the price right around the intermediate moving average with neutral momentum. Operating cash flow for 2025 was reported at $5.1 billion, which is materially stronger than the bottom-line loss and suggests Centene can still generate cash even while reported net income is under pressure. For readers screening on valuation, the negative P/E and negative ROE are warning flags that “cheap” ratios require an earnings-recovery thesis rather than a simple value purchase.

Strategic priorities & outlook

Centene’s most recent 10-K filing outlines several near-term operational priorities. First, the company intends to continue refining its Medicare footprint so that it overlaps more closely with its Medicaid operations, while expanding Dual Eligible Special Needs Plans (D-SNP) offerings to drive long-term growth. Management is also maintaining an enterprise-level focus on D-SNP, including integrated products aligned with Centers for Medicare & Medicaid Services (CMS) requirements taking effect through 2030.

On the policy front, Centene says it will advocate for legislation and regulation that preserves affordable Medicaid and Marketplace coverage, as well as cost-effective, high-quality care for PDP members. Operationally, it plans to implement 2026 corrective Marketplace pricing actions in states covering 95% of Marketplace membership, and to expand Ambetter Health Solutions / ICHRA-compatible off-exchange coverage from 6 states to 13 states. Finally, the company signed a definitive agreement in December 2025 to divest the remaining Magellan Health businesses, indicating a portfoliocleanup effort alongside the core growth initiatives.

Macro & geopolitical exposure

Because the industry classification is Medical - Healthcare Plans, Centene’s macro exposure is overwhelmingly regulatory and policy-driven rather than commodity or trade-driven. Revenue depends on federal and state Medicaid funding decisions, CMS reimbursement and rate-setting for Medicare Advantage and PDP products, Affordable Care Act (ACA) marketplace rules, and potential changes to healthcare legislation. State budget cycles are particularly relevant to Medicaid, while Medicare Advantage margins can shift with annual CMS rate announcements and Star Ratings.

Managed-care companies are also exposed to medical-cost inflation and utilization trends, which can move faster than premium pricing. Currency and direct commodity-price risks are generally minor for a domestic health insurer, but labor costs in the healthcare sector and provider-contract negotiations are persistent variables. Geopolitical shocks do not usually move this industry directly, but any legislation or executive action that changes eligibility, subsidy levels, or reimbursement formulas can quickly alter earnings power across the entire sector.

Recent developments

Recent headlines have mostly centered on valuation and Medicare product planning. On October 5, 2026, Zacks published “Are Investors Undervaluing Centene (CNC) Right Now?,” which screened the stock through a value lens. On October 1, 2026, Zacks included CNC in “Best Growth Stocks to Buy for October 1st,” and on September 30, 2026, the same outlet listed it among “5 Low P/B Stocks With Attractive Value and Strong Growth Potential.” Also on October 1, 2026, PRNewswire carried the headline “Wellcare Unveils 2027 Medicare Offerings Focused on Affordability and Integrated Care,” linking the company’s Medicare brand to its strategic emphasis on integrated, affordable care.

These headlines do not constitute endorsements or ratings changes, but they do illustrate how the stock is being discussed: as a value/growth-hybrid candidate with a business mix tilted toward government-sponsored programs and a 2027 Medicare product refresh intended to support the D-SNP and integrated-care strategy.

Earnings behavior & post-earnings drift

Centene’s recent earnings record has been strong on a binary beat/miss basis. Over the last eight reported quarters, the company beat estimates in seven of the eight periods, giving it an 88% beat rate. The average earnings surprise across those quarters was 63.1%. The average 5-day price move in the five trading days after the report was +2.83%, and the drift direction is classified as “up.”

The four most recent quarters show how high-magnitude beats do not always translate into immediate price gains:

• On July 28, 2026, Centene reported actual EPS of $2.51 versus an estimate of $1.09, a 130.3% surprise. The stock fell 3.27% the next day and rose just 0.25% over the following five days.
• On April 28, 2026, actual EPS was $3.37 against an estimate of $2.23, a 51.1% surprise. The stock gained 8.9% the next day and 6.88% over the next five days.
• On February 6, 2026, actual EPS was negative $1.19 versus an estimate of negative $1.22007, a 2.5% surprise. The stock fell 1.09% the next day but gained 5.51% over the following five days.
• On October 29, 2025, actual EPS was $0.50 versus an estimate of negative $0.14475, a 445.4% surprise. The stock still dropped 6.21% the next day and 1.34% over the next five days.

Looking ahead, the next scheduled report is October 27, 2026, before the market open, with an unofficial consensus EPS estimate of $0.09574. The historical beat rate and positive average drift are useful context, but the wide dispersion of next-day reactions shows that the market’s real expectation can differ materially from the published estimate and that forward guidance often matters more than the headline beat.

For a deeper dive beyond these data points and trend observations, readers should review the full institutional verdict, including analyst ratings, forward estimate revisions, and sector-relative comparisons, to form their own comprehensive view of Centene’s risk/reward profile.